格隆汇12月24日｜据36氪，近日，礼来公司旗下创新药替尔泊肽被正式纳入新版国家医保目录，带动国 内降糖与减重药物市场迎来新一轮降价。经实测，在替尔泊肽医保价落地前，部分线上医药平台已率先 启动降价预售活动。 美团买药显示，替尔泊肽10mg规格预售到手价低至450元，相当于此前价格的2折左右。同时，司美格 鲁肽等其他GLP-1药物线上价格也出现不同程度调整，医保政策对院外市场价格的传导效应逐步显现。 ...

Core Insights - Global pharmaceutical companies Eli Lilly and Novo Nordisk are competing to establish their dominance in India's rapidly growing obesity drug market before the introduction of cheaper generic alternatives in March next year [1] Company Focus - Eli Lilly and Novo Nordisk are recognized as major players in the obesity drug sector, indicating their significant investment and strategic initiatives aimed at capturing market share in India [1]

Core Insights - Novo Nordisk is entering the oral GLP-1 market with its new pill, which may provide an opportunity to gain market share despite not dramatically changing the competitive landscape [2][3] - The success of Novo's pill will depend on its manufacturing capabilities and the ability to meet demand, as the active ingredient requires significantly more quantity compared to injectables [4][5][6] - Consumer preferences will be tested in 2026, determining whether they favor the convenience of a pill over the effectiveness of injectables [7][8][9] Manufacturing and Supply - Novo has begun manufacturing the active ingredient for its pill in North Carolina, but there are concerns about its ability to meet demand due to the complexity of the molecule [4][5] - The pill formulation requires approximately 70 times more of the active ingredient to be effective compared to injectable forms, which poses additional manufacturing challenges [6] Market Dynamics - The introduction of Novo's pill and Eli Lilly's upcoming orforglipron will create a competitive environment where consumer preferences will play a crucial role [3][7] - Eli Lilly has demonstrated effective marketing strategies with its own products, which may influence consumer choices in the market [8][9]

The U.S. Centers for Medicare and Medicaid Services said on Tuesday it will negotiate drug pricing with manufacturers of GLP-1 medications to expand access to the drugs that help with weight loss. ...

Core Viewpoint - The healthcare sector has shown resilience despite challenges, with optimism returning in the latter half of the year, particularly in the biopharmaceutical segment, which is experiencing one of its best performances in a decade [2][3]. Company Analysis - Novo Nordisk is facing a competitive landscape in the obesity treatment market, particularly against Eli Lilly, which has been rated more favorably by analysts [4]. - The new WGOI pill from Novo is noted for its higher concentration of active pharmaceutical ingredient (API), which is 25 milligrams compared to the 2.4 milligrams in Lilly's shot, suggesting a potential for greater weight loss [5][7]. - Concerns exist regarding revenue growth for Novo in the upcoming year, as the market is cautious about the company's ability to maintain its competitive edge [5][7]. - The convenience of the WGOI pill, which requires taking it first thing in the morning, may present challenges compared to Lilly's orphagon pill that does not have food effect issues [6]. Industry Landscape - The obesity treatment market is substantial, with over 140 million obese individuals in the U.S., indicating significant room for growth for both Novo and Lilly [10]. - The introduction of longer-acting competitors, such as Pfizer, could further impact market dynamics and competition in the obesity treatment space [11].

The approval of Novo Nordisk's (NYSE:NVO) oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 market without requiring investors to choose one specific company.• What should traders watch with XLV?Broad funds like the Health Care Select Sector SPDR Fund (NYSE:XLV) and the Vanguard Health Care ETF (NYSE:VHT) offer diversified exposure to major drugmakers, such as Novo Nordisk and Eli Lilly And Co (NYSE:LLY) , as well as insurers and health care ...

HSBC's senior research analyst Rajesh Kumar believes Novo Nordisk (NYSE: NVO) "might have an edge†over rival Eli Lilly (NYSE: LLY) heading into 2026. His remarks arrive shortly after the Danish pharm... ...

每经AI快讯，12月23日，礼来公司股价逆转盘前走势，目前上涨1%。 （文章来源：每日经济新闻） ...

Industry Overview - The drug and biotech sector has shown recovery after a weak first half, with large drugmakers signing pricing agreements with the Trump administration [1] - Dealmaking activity surged in the second half, boosting investor confidence, with the Large Cap Pharmaceuticals industry outperforming the S&P 500 in the past three months [1][4] - Innovation is at its peak, particularly in areas like obesity, cell and gene therapy, and next-gen oncology treatments, attracting investor attention [2] - Despite headwinds such as pipeline setbacks and regulatory risks, the outlook for growth in 2026 remains favorable due to rapid innovation and increased use of AI in drug development [2] Eli Lilly - Eli Lilly has achieved significant success with its tirzepatide medicines, including diabetes drug Mounjaro and weight loss medicine Zepbound, which are key revenue drivers [6][7] - Strong sales growth in 2025 is attributed to international market launches and improved production, with continued demand expected in 2026 [7] - Lilly is investing in obesity treatments with new molecules in clinical development, including orforglipron and retatrutide, with regulatory applications filed for orforglipron [8][9] - Despite challenges like declining product prices and competition in the GLP-1 market, Lilly's stock has risen 39.3% year to date, with 2026 earnings estimates improving from $30.78 to $33.61 per share [10] Johnson & Johnson - J&J has shown strong operational performance in 2025, with double-digit revenue growth from key brands despite the loss of exclusivity for Stelara [11] - The Innovative Medicine segment is expected to accelerate growth in 2026, driven by key products and new launches [12] - J&J's MedTech business has improved, with growth driven by acquired cardiovascular businesses and new product launches expected to contribute to 2026 growth [13][14] - The company has advanced its pipeline significantly and is on an acquisition spree, with a Zacks Rank of 2 (Buy) and a stock rise of 43.3% year to date [17] AbbVie - AbbVie faces declining sales from Humira due to loss of exclusivity but has successfully launched new immunology medicines Skyrizi and Rinvoq, generating combined sales of $18.5 billion in the first nine months of 2025 [18][19] - Strong market growth and new indications for these drugs are expected to drive future growth, alongside contributions from newer drugs [20] - AbbVie anticipates a high single-digit CAGR through 2029, supported by robust performance from Skyrizi and Rinvoq, with a Zacks Rank of 3 and a stock rise of 28.2% year to date [21][22] Amgen - Amgen's revenue growth is driven by key medicines like Repatha and new biosimilars, compensating for declines from mature drugs [23][24] - The company is focusing on obesity treatments with its candidate MariTide, which differentiates itself with a convenient dosing method [24] - Amgen's stock has risen 27.3% year to date, with 2026 earnings estimates increasing from $21.43 to $21.62 per share [25] AstraZeneca - AstraZeneca has several blockbuster drugs exceeding $1 billion in sales, with newer products contributing to growth despite losses from mature brands [26][27] - The company expects to achieve industry-leading top-line growth through 2030, with plans to launch 20 new medicines and generate $80 billion in total revenues [28] - AstraZeneca faces challenges such as competition and regulatory impacts but maintains a stable earnings estimate of $5.15 per share for 2026, with a stock rise of 10.7% year to date [29][30]

PLEASED TO SAY IS THE CEO OF NOVO NORDISK, MIKE DOUSTDAR. GREAT TO HAVE YOU WITH US. JUST TO SET THE SCENE WHEN IT COMES TO THE U.S. MARKET, YOU HAVE BEEN LOSING SHERRY TO ELI LILLY FOR A COUPLE YEARS NOW. WITH THIS APPROVAL, YOU HAVE AN IMPORTANT FIRST MOVER ADVANTAGE WHEN IT COMES TO ORAL GLP-1'S.GIVEN THAT YOU EXPECT TO SELL THE PILL VERSION OF WEGOVY IN JANUARY AND ELI LILLY IS NOT DUE UNTIL MARCH, HOW DO YOU PLAN TO MAKE THE MOST OF THIS HEAD START. MIKE: THANK YOU FOR HAVING ME. AS THEY SAY, CHRISTMAS ...